Close Menu

After the Sequence

At the Loom, Carl Zimmer bemoans what he dubs the "Yet-Another-Genome Syndrome." Sequencing a genome, he writes, used to be different — it took forever to do and was a big deal when it came out — but with next-generation sequencing, it takes comparatively no time at all, yet they still generate tons of press releases and news articles. It's what comes after the sequencing, Zimmer says, that is interesting.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.